Impact of p53 on Doxorubicin-Induced Heart Damage
Author Information
Author(s): Feridooni Tiam, Hotchkiss Adam, Remley-Carr Sarah, Saga Yumiko, Pasumarthi Kishore B. S.
Primary Institution: Dalhousie University
Hypothesis
Does downregulation of p53 in cardiomyocytes reduce myocardial fibrosis and apoptosis caused by Doxorubicin?
Conclusion
The study found that loss of p53 in cardiomyocytes does not prevent Doxorubicin-induced myocardial damage and fibrosis.
Supporting Evidence
- CKO mice treated with Dox showed higher levels of fibrosis compared to controls.
- Apoptosis was observed in both wild type and CKO mice after Dox treatment.
- Dox treatment did not prevent the decrease in α-tubulin levels in CKO mice.
Takeaway
Researchers wanted to see if removing a protein called p53 from heart cells would help protect the heart from damage caused by a cancer drug called Doxorubicin, but it didn't work.
Methodology
The study used a conditional knockout mouse model to assess the effects of Doxorubicin on myocardial and perivascular apoptosis and fibrosis.
Potential Biases
Potential bias in interpreting results due to the specific genetic model used.
Limitations
The study did not explore long-term effects of p53 ablation on cardiac function beyond the acute phase.
Participant Demographics
Mice aged 11–15 weeks were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website